(+/-)-1-amino-2,4-butanediol | 130239-34-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (+/-)-1-amino-2,4-butanediol
• 英文别名: aminomethyl-1,3-propanediol；4-amino-1,3-butanediol；2-Hydroxyethylethanolamine；4-aminobutane-1,3-diol
• CAS: 130239-34-8
• 化学式: C₄H₁₁NO₂
• 分子量: 105.137
• InChiKey: AZWLGPJBVAQRHW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.7
• 重原子数：
  7
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  66.5
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-[3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-3H-[1,3,4]oxadiazol-2-one 、 (+/-)-1-amino-2,4-butanediol 以 乙醇 为溶剂， 生成 2-(3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzoyl)-N-(2,4-dihydroxybutyl)hydrazine-1-carboxamide
  参考文献：
  名称：

  2-Alkylamino- and alkoxy-substituted 2-amino-1,3,4-oxadiazoles—O-Alkyl benzohydroxamate esters replacements retain the desired inhibition and selectivity against MEK (MAP ERK kinase)

  摘要：

  This paper reports a second generation MEK inhibitor. The previously reported potent and efficacious MEK inhibitor, PD-184352 (CI-1040), contains an integral hydroxamate moiety. This compound suffered from less than ideal solubility and metabolic stability. An oxadiazole moiety behaves as a bioisostere for the hydroxamate group, leading to a more metabolically stable and efficacious MEK inhibitor.

  DOI：

  10.1016/j.bmcl.2008.10.015
• 作为产物：
  描述：

  1-Phthalimino-butan-2,4-diol 在 weakly basic anion exchange resin (DIAION WA-20) 、 水 作用下， 以 乙醇 为溶剂， 反应 1.0h， 以92%的产率得到(+/-)-1-amino-2,4-butanediol
  参考文献：
  名称：

  Hydrolysis ofN-Substituted Phthalimides Using Anion Exchange Resins. Synthesis of Hydroxy-Substituted Aliphatic Primary Amines (Amino Alcohols)

  摘要：

  使用阴离子交换树脂成功地将 N-取代邻苯二甲酰亚胺水解为相应的羟基取代脂肪族伯胺（氨基醇）。事实证明，这种方法对于难以分离的水溶性产品非常有用。

  DOI：

  10.1055/s-1990-27000

文献信息

• BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1
  申请人：Furet Pascal

  公开号：US20150126485A1

  公开（公告）日：2015-05-07

  The present invention relates to compounds of formula (I): in which Y, Y, R, R 2, R 3 and R 4 are defined in the Summary of the Invention; capable of inhibiting the tyrosine kinase enzymatic activity of the Abelson protein (ABL1), the Abelson-related protein (ABL2) and related chimeric proteins, in particular BCR-ABL1. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers.

  本发明涉及式（I）的化合物：其中Y，Y，R，R2，R3和R4在本发明的摘要中定义；能够抑制Abelson蛋白（ABL1），Abelson相关蛋白（ABL2）和相关嵌合蛋白的酪氨酸激酶酶活性，特别是BCR-ABL1。本发明还提供了制备本发明化合物的方法，包括这种化合物的制药制剂以及使用这种化合物治疗癌症的方法。
• Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1
  申请人：Furet Pascal

  公开号：US09340537B2

  公开（公告）日：2016-05-17

  The present invention relates to compounds of formula (I): in which Y, Y, R, R 2, R 3 and R 4 are defined in the Summary of the Invention; capable of inhibiting the tyrosine kinase enzymatic activity of the Abelson protein (ABL1), the Abelson-related protein (ABL2) and related chimeric proteins, in particular BCR-ABL1. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers.

  本发明涉及式（I）的化合物：其中Y，Y，R，R2，R3和R4在本发明摘要中定义；能够抑制Abelson蛋白（ABL1），Abelson相关蛋白（ABL2）和相关嵌合蛋白的酪氨酸激酶酶活性，特别是BCR-ABL1。本发明还提供了制备本发明化合物的方法，包括这种化合物的制药配制物以及使用这种化合物治疗癌症的方法。
• Structure-Activity Relationships of Cytotoxic Cholesterol-Modified DNA Duplexes
  作者：Michael W. Reed、Eugeny Lukhtanov、Vladimir Gorn、Deborah D. Lucas、James H. Zhou、S. Balakrishna Pai、Yung-chi Cheng、Rich B. Meyer

  DOI：10.1021/jm00022a025

  日期：1995.10

  Short DNA duplexes with cholesterol linked at the 3'-terminus of each strand have unique, selective cytotoxic properties. The structural requirements for biological activity were explored through chemical synthesis of analogs and testing in cultured hepatoma cells. Effects of modifications to the sequence, backbone, 3'-sterol, 3'-linker, and 5'-terminus were evaluated. Self-complementary 3'-modified oligodeoxynucleotide (ODN) 10-mers were prepared from solid supports bearing the modification and linker of interest. Any changes to the normal phosphodiester backbone were poorly tolerated. The presence of cholesterol or a closely related sterol was an absolute requirement for activity. The length and position of attachment of the linker to cholesterol was important, with longer linkers showing reduced activity. Large, lipophilic groups at the 5'-terminus gave reduced cytotoxicity and poor solubility properties. The short length and unique structure of these ODNs allowed efficient automated synthesis on a 400 mu mol scale and simplified purification.
• KURIYAMA, NAOHIRO;INOUE, YOSHIHARU;KITAGAWA, KEISHI, SYNTHESIS,(1990) N, C. 735-738
  作者：KURIYAMA, NAOHIRO、INOUE, YOSHIHARU、KITAGAWA, KEISHI

  DOI：——

  日期：——
• [EN] N-HETEROCYLIC GPCR RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE<br/>[FR] AGONISTES DU RÉCEPTEUR RCPG N-HÉTÉROCYLIQUE, COMPOSITIONS PHARMACEUTIQUES LES COMPRENANT ET LEURS PROCÉDÉS D'UTILISATION
  申请人：[en]CARMOT THERAPEUTICS, INC.

  公开号：WO2024026338A1

  公开（公告）日：2024-02-01

  Provided herein are GLP-1 receptor modulator compounds, pharmaceutical compositions, methods of their preparation, and methods of their use in treatment, and/or diagnosis.